Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: A preliminary study

doi:10.1016/j.neuroscience.2006.01.054

Neuroscience

Volume 139, Issue 4, 2006, Pages 1289-1300

https://doi.org/10.1016/j.neuroscience.2006.01.054 Get rights and content

Abstract

Both neural development and prefrontal cortex function are known to be abnormal in schizophrenia and bipolar disorder. In order to test the hypothesis that these features may be related with genes that regulate neuronal migration, we analyzed two genomic regions: the lissencephaly critical region (chromosome 17p) encompassing the LIS1 gene and which is involved in human lissencephaly; and the genes related to the platelet-activating-factor, functionally related to LIS1, in 52 schizophrenic patients, 36 bipolar I patients and 65 normal control subjects. In addition, all patients and the 25 control subjects completed a neuropsychological battery. Thirteen (14.8%) patients showed genetic variations in either two markers related with lissencephaly or in the platelet-activating-factor receptor gene. These patients performed significantly worse in the Wisconsin Card Sorting Test–Perseverative Errors in comparison with patients with no lissencephaly critical region/platelet-activating-factor receptor variations. The presence of lissencephaly critical region/platelet-activating-factor receptor variations was parametrically related to perseverative errors, and this accounted for 17% of the variance (P=0.0001). Finally, logistic regression showed that poor Wisconsin Card Sorting Test–Perseverative Errors performance was the only predictor of belonging to the positive lissencephaly critical region/platelet-activating-factor receptor group. These preliminary findings suggest that the variations in genes involved in neuronal migration predict the severity of the prefrontal cognitive deficits in both disorders.

Section snippets

Subjects

A written informed consent was obtained from all participants following an explanation of study procedures. The ethics committee of the University Clinic Hospital of Valencia (Spain) approved the research protocol. All subjects were aged between 18 and 60 years and were unrelated individuals of European ancestral birth, who were educated in Spain. Patients were recruited if they fulfilled the Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV; American Psychiatric

Results

In comparison with bipolar disorder patients, patients with schizophrenia were significantly younger (mean age±sd=34.8±7.8; 40.9±11.1 years, respectively), were younger when the onset of the disorder took place (mean age at onset±sd=25.7±6.7 and 29.1±9.9, respectively), and they showed more positive (mean PANSS-positive±sd=13.6±5.5 and 9.6±4.7, respectively) and negative (mean PANSS-negative±sd=21.5±8.6 and 10.3±4.1, respectively) symptoms. No differences were found in the remaining variables

Discussion

Our analysis revealed a subgroup of schizophrenic and bipolar disorder type I patients with genetic variations in the LCR region of chromosome 17p, which is implicated in lissencephaly sequence and in the Miller-Dieker syndrome (Toyo-oka et al., 2003), and is a risk for schizophrenia (p53 gene; Chiu et al 2001, Papiol et al 2004, Ni et al 2005).

Moreover, schizophrenic subjects also showed genetic variations in the PTAFR coding region in chromosome 1p. Several authors have hypothesized that the

Acknowledgments

This study was supported by the following: Lilly, S.A. (Spain), the Stanley Medical Research Institute (Bethesda, MD, USA), European Union grants U.E. QLG2-CT-1999-00793; UE QLRT-1999-31556; UE QLRT-1999-31625; QLRT-2000-02310; Spanish grants DIGESIC-MEC BFI2002-02979/BFU2005-09085 to S.M.; BFI2002-03467 to E.G.-B. and FIS-MSC (PI051293) and GV2005-303 to R.T.-S. We thank Lourdes Fañanás, Araceli Rosa, Ignacio Mata, Héctor J. Caruncho and Manuel Gómez-Beneyto for their helpful advice.

References (84)

E.G. Altman et al.
The Clinician-Administered Rating Scale for Mania (CARS-M)development, reliability, and validity
Biol Psychiatry
(1994)
R. Bell et al.
Systematic screening of the LDL-PLA2 gene for polymorphic variations and case-control analysis in schizophrenia
Biochem Biophys Res Commun
(1997)
D.H. Blackwood et al.
Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genesclinical and P300 findings in a family
Am J Hum Genet
(2001)
N.J. Brandon et al.
Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein compleximplications for schizophrenia and other major neurological disorders
Mol Cell Neurosci
(2004)
C. Cardoso et al.
Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3
Am J Hum Genet
(2003)
H.J. Chiu et al.
Association study of the p53-gene Pro72Arg polymorphism in schizophrenia
Psychiatry Res
(2001)
E. Costa et al.
Should allosteric positive modulators of GABA(A) receptors be tested in the treatment of schizophrenia?
Schizophr Res
(2005)
C.A. Hodgkinson et al.
Disrupted in schizophrenia 1 (DISC1)association with schizophrenia, schizoaffective disorder, and bipolar disorder
Am J Hum Genet
(2004)
A. Honda et al.
Isolated lissencephaly sequence with balanced chromosome translocation involving 17p13.3
Brain Dev
(1998)
M.B. Knable et al.
Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium
Brain Res Bull
(2001)

K.R. Merikangas et al.

Future of genetics of mood disorders research

Biol Psychiatry

(2002)

X. Ni et al.

Human p53 tumor suppressor gene (TP53) and schizophreniacase-control and family studies

Neurosci Lett

(2005)

T. Ohtsuki et al.

Lack of evidence for associations between plasma platelet-activating factor acetylhydrolase deficiency and schizophrenia

Psychiatry Res

(2002)

J. Pahnke et al.

Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells

Exp Cell Res

(2004)

S. Papiol et al.

Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits

Neurosci Lett

(2004)

V. Peralta et al.

Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia

Psychiatry Res

(1994)

D.T. Pilz et al.

Fluorescence in situ hybridization analysis with LIS1 specific probes reveals a high deletion mutation rate in isolated lissencephaly sequence

Genet Med

(1998)

C.E. Schwartz et al.

Localization of the Miller-Dieker critical region is proximal to locus D17S34 (p144D6) in 17p13.3

Genomics

(1990)

T. Shu et al.

Ndel1 operates in a common pathway with LIS1 and cytoplasmic dynein to regulate cortical neuronal positioning

Neuron

(2004)

D. St. Clair et al.

Association within a family of a balanced autosomal translocation with major mental illness

Lancet

(1990)

R. Tabarés-Seisdedos et al.

Specific executive/attentional deficits in patients with schizophrenia or bipolar disorder who have a positive family history of psychosis

J Psychiatry Res

(2003)

C. Tarricone et al.

Coupling PAF signaling to dynein regulationstructure of LIS1 in complex with PAF-acetylhydrolase

Neuron

(2004)

W.H. Toh et al.

Relief of p53-mediated telomerase suppression by p73 (2005)

J Biol Chem

(2005)

D.R. Weinberger et al.

Prefrontal neurons and the genetics of schizophrenia

Biol Psychiatry

(2001)

R. Agarwala et al.

A fast and scalable radiation hybrid map construction and integration strategy

Genome Res

(2000)

Diagnostic and statistical manual of mental disorders

(1994)

A. Ardilla et al.

Neuropsychological evaluation of the Spanish speaker

(2004)

A.H. Assadi et al.

Interaction of reelin signaling and Lis1 in brain development

Nat Genet

(2003)

V. Balanzá-Martínez et al.

Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patientsa 3-year follow-up study

Psychother Psychosom

(2005)

J.R. Batanian et al.

Rapid diagnosis of Miller-Dieker syndrome and isolated lissencephaly sequence by the polymerase chain reaction

Hum Genet

(1990)

P. Bebbington et al.

The psychosis screening questionnaire

Int J Methods Psychiatr Res

(1995)

W.H. Berrettini

Bipolar disordersreview of molecular genetic linkage studies

G.J. Bix et al.

Platelet-activating factor receptor stimulation disrupts neuronal migration in vitro

J Neurosci

(1998)

J.H. Callicott et al.

Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia

Proc Natl Acad Sci U S A

(2005)

C. Chen et al.

Platelet-activating factor inhibits ionotropic GABA receptor activity in cultured hippocampal neurons

Neuroreport

(1999)

L. Citrome et al.

Toward convergence in the medication treatment of bipolar disorder and schizophrenia

Harv Rev Psychiatry

(2005)

T.J. Crow

From Kraepelin to Kretschmer leavened by Schneiderthe transition from categories of psychosis to dimensions of variation intrinsic to Homo sapiens

Arch Gen Psychiatry

(1998)

C. Daban et al.

Specificity of cognitive deficits in bipolar disorder versus schizophreniaa systematic review

Psychother Psychosom

(2006)

M.F. Egan et al.

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

Proc Natl Acad Sci U S A

(2001)

J. Endicott et al.

Family history RDC

(1978)

S.H. Fatemi et al.

Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression

Mol Psychiatry

(2000)

D.R. Grayson et al.

Reelin promoter hypermethylation in schizophrenia

Proc Natl Acad Sci U S A

(2005)

Cited by (43)

Clinical analysis of PAFAH1B1 gene variants in pediatric patients with epilepsy
2024, Seizure
PAFAH1B1, also known as LIS1, is associated with type I lissencephaly in humans, which is a severe developmental brain disorder believed to result from abnormal neuronal migration. Our objective was to characterize the genotypes and phenotypes of PAFAH1B1-related epilepsy.
We conducted a comprehensive analysis of the medical histories, magnetic resonance imaging findings, and video-electroencephalogram recordings of 11 patients with PAFAH1B1 variants at the Neurology Department of Beijing Children's Hospital from June 2017 to November 2022.
The age of onset of epilepsy ranged from 2 months to 4 years, with a median onset age of 5 months. Among these 11 patients (comprising 6 boys and 5 girls), all were diagnosed with lissencephaly type 1. Predominantly, generalized tonic-clonic and spasm seizures characterized PAFAH1B1-related epilepsy. Additionally, 10 out of the 11 patients exhibited severe developmental disorders. All patients exhibited de novo variants, with three individuals displaying 17p13.3 deletions linked to haploinsufficiency of PAFAH1B1. Four variants were previously unreported. Notably, three patients with 17p13.3 deletions displayed developmental delay and drug resistant epilepsy, whereas the single patient with mild developmental delay, Intelligence Quotient (IQ) 57 and well-controlled seizures had a splicing-site variant.
The severity of the phenotype in patients with PAFAH1B1 variants ranged from drug-responsive seizures to severe epileptic encephalopathy. These observations underscore the clinical heterogeneity of PAFAH1B1-related disorders, with most patients exhibiting developmental disorders. Moreover, the severity of epilepsy appears to be linked to genetic variations.
Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome
2023, Brain Research Bulletin
After five waves of coronavirus disease 2019 (COVID-19) outbreaks, it has been recognized that a significant portion of the affected individuals developed long-term debilitating symptoms marked by chronic fatigue, cognitive difficulties (“brain fog”), post-exertional malaise, and autonomic dysfunction. The onset, progression, and clinical presentation of this condition, generically named post-COVID-19 syndrome, overlap significantly with another enigmatic condition, referred to as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Several pathobiological mechanisms have been proposed for ME/CFS, including redox imbalance, systemic and central nervous system inflammation, and mitochondrial dysfunction. Chronic inflammation and glial pathological reactivity are common hallmarks of several neurodegenerative and neuropsychiatric disorders and have been consistently associated with reduced central and peripheral levels of plasmalogens, one of the major phospholipid components of cell membranes with several homeostatic functions. Of great interest, recent evidence revealed a significant reduction of plasmalogen contents, biosynthesis, and metabolism in ME/CFS and acute COVID-19, with a strong association to symptom severity and other relevant clinical outcomes. These bioactive lipids have increasingly attracted attention due to their reduced levels representing a common pathophysiological manifestation between several disorders associated with aging and chronic inflammation. However, alterations in plasmalogen levels or their lipidic metabolism have not yet been examined in individuals suffering from post-COVID-19 symptoms. Here, we proposed a pathobiological model for post-COVID-19 and ME/CFS based on their common inflammation and dysfunctional glial reactivity, and highlighted the emerging implications of plasmalogen deficiency in the underlying mechanisms. Along with the promising outcomes of plasmalogen replacement therapy (PRT) for various neurodegenerative/neuropsychiatric disorders, we sought to propose PRT as a simple, effective, and safe strategy for the potential relief of the debilitating symptoms associated with ME/CFS and post-COVID-19 syndrome.
Neurodevelopmental origins of bipolar disorder: IPSC models
2016, Molecular and Cellular Neuroscience
Citation Excerpt :
Perhaps the strongest evidence of a neurodevelopmental contribution to BP comes from several reports of cell migration abnormalities in the neocortex, including the presence of neuronal dysplasias and heterotopias in BP brain (Beckmann and Jakob, 1991; Tabares-Seisdedos et al., 2006, 2008; Uribe and Wix, 2012). This is consistent with reports of altered expression of molecules associated with cortical cell migrations including Reelin (Guidotti et al., 2000; Folsom and Fatemi, 2013; Lubbers et al., 2014), DISC1 (Munoz-Estrada et al., 2015), association with alterations in lissencephaly genes (Tabares-Seisdedos et al., 2006, 2008), and many other reports of alterations in the expression of molecules associated with the cell surface and extracellular matrix identified in large databases (below) in BP. Synaptic pruning and dendritic alterations peak during late adolescence and are thought to reflect innate neuroplasticity in the brain.
Bipolar disorder (BP) is a chronic neuropsychiatric condition characterized by pathological fluctuations in mood from mania to depression. Adoption, twin and family studies have consistently identified a significant hereditary component to BP, yet there is no clear genetic event or consistent neuropathology. BP has been suggested to have a developmental origin, although this hypothesis has been difficult to test since there are no viable neurons or glial cells to analyze, and research has relied largely on postmortem brain, behavioral and imaging studies, or has examined proxy tissues including saliva, olfactory epithelium and blood cells. Neurodevelopmental factors, particularly pathways related to nervous system development, cell migration, extracellular matrix, H3K4 methylation, and calcium signaling have been identified in large gene expression and GWAS studies as altered in BP. Recent advances in stem cell biology, particularly the ability to reprogram adult somatic tissues to a pluripotent state, now make it possible to interrogate these pathways in viable cell models. A number of induced pluripotent stem cell (iPSC) lines from BP patient and healthy control (C) individuals have been derived in several laboratories, and their ability to form cortical neurons examined. Early studies suggest differences in activity, calcium signaling, blocks to neuronal differentiation, and changes in neuronal, and possibly glial, lineage specification. Initial observations suggest that differentiation of BP patient-derived neurons to dorsal telencephalic derivatives may be impaired, possibly due to alterations in WNT, Hedgehog or Nodal pathway signaling. These investigations strongly support a developmental contribution to BP and identify novel pathways, mechanisms and opportunities for improved treatments.
The clinical implications of cognitive impairment and allostatic load in bipolar disorder
2013, European Psychiatry
Citation Excerpt :
Neurocognition has been the focus of extensive research in schizophrenia and, more recently, in bipolar disorder (BD) [29,39,73,76,115,129]. Neuropsychological testing may represent a tool able to identify potential neuroimaging markers and endophenotypes [23,46,124,149] and to better understand the underlying neurophysiology [49]. However, only lately the highly consistent findings from research began to be applied to clinical practice, and many clinicians are not much aware of how neurocognitive deficits affect their patients’ daily life, and, importantly, what can be done to prevent or at least mitigate cognitive impairment.
Allostatic load (AL) relates to the neural and bodily “wear and tear” that emerge in the context of chronic stress. This paper aims to provide clinicians with a comprehensive overview of the role of AL in patophysiology of bipolar disorder (BD) and its practical implications.
PubMed searches were conducted on English-language articles published from 1970 to June 2011 using the search terms allostatic load, oxidative stress, staging, and bipolar disorder cross-referenced with cognitive impairment, comorbidity, mediators, prevention.
Progressive neural and physical dysfunction consequent to mood episodes in BD can be construed as a cumulative state of AL. The concept of AL can help to reconcile cognitive impairment and increased rates of clinical comorbidities that occur over the course of cumulative BD episodes.
Data on transduction of psychosocial stress into the neurobiology of mood episodes converges to the concept of AL. Mood episodes prevention would not only alleviate emotional suffering, but also arrest the cycle of AL, cognitive decline, physical morbidities and, eventually, related mortality. These objectives can be achieved by focusing on effective prophylaxis from the first stages of the disorder, providing mood-stabilizing agents and standardized psychoeducation and, potentially, addressing cognitive deficits by the means of specific medication and neuropsychological interventions.
Neuronal migration, apoptosis and bipolar disorder
2012, Revista de Psiquiatria y Salud Mental
El trastorno bipolar es considerado, al igual que la mayoría de los trastornos psiquiátricos, una enfermedad del neurodesarrollo. Durante dicho período, existe una marcada tasa de nacimiento y muerte neuronal. En el caso particular de los procesos que determinan la muerte neuronal, es sabido que aquellas neuronas que establecen conexiones sinápticas aberrantes deben ser eliminadas del sistema nervioso central. El trastorno bipolar cursa con un déficit de interneuronas GABAérgicas en la corteza cerebral, acompañado de una sobreexpresión de genes proapoptóticos, así como una alteración en la expresión de moléculas que median la migración de dichas neuronas y su inclusión en sinapsis funcionales durante el estadío fetal. Aquí será revisado el rol de dichas moléculas sobre las vías de muerte neuronal por apoptosis en la procura de establecer hipótesis biológicas de la génesis del trastorno bipolar.
Bipolar disorder, like the majority of psychiatric disorders, is considered a neurodevelopment disease of neurodevelopment. There is an increased rate of neuronal birth and death during this development period. In the particular case of the processes that determine neuronal death, it is known that those neurons that establish connections have to be removed from the central nervous system. There is a deficit of GABAergic interneurons in the cerebral cortex in bipolar disorder, accompanied by overexpression of proapoptic genes. There is also an alteration in the expression of molecules that mediate in the migration of these neurons and their inclusion in functional synapsis during the foetal stage. The role of these molecules in the neuronal death pathways by apoptosis will be reviewed here in an attempt to establish biological hypotheses of the genesis of bipolar disorder.
Tertiarism in psychiatry: The Barcelona Clínic bipolar disorders programme
2011, Revista de Psiquiatria y Salud Mental

View all citing articles on Scopus

¹: These authors contributed equally to this work.

View full text

Cellular neuroscienceVariations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: A preliminary study

Abstract

Section snippets

Subjects

Results

Discussion

Acknowledgments

Biol Psychiatry

Biochem Biophys Res Commun

Am J Hum Genet

Mol Cell Neurosci

Am J Hum Genet

Psychiatry Res

Schizophr Res

Am J Hum Genet

Brain Dev

Brain Res Bull

Biol Psychiatry

Neurosci Lett

Psychiatry Res

Exp Cell Res

Neurosci Lett

Psychiatry Res

Genet Med

Genomics

Neuron

Lancet

J Psychiatry Res

Neuron

J Biol Chem

Biol Psychiatry

A fast and scalable radiation hybrid map construction and integration strategy

Genome Res

Diagnostic and statistical manual of mental disorders

Neuropsychological evaluation of the Spanish speaker

Interaction of reelin signaling and Lis1 in brain development

Nat Genet

Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patientsa 3-year follow-up study

Psychother Psychosom

Rapid diagnosis of Miller-Dieker syndrome and isolated lissencephaly sequence by the polymerase chain reaction

Hum Genet

The psychosis screening questionnaire

Int J Methods Psychiatr Res

Bipolar disordersreview of molecular genetic linkage studies

Platelet-activating factor receptor stimulation disrupts neuronal migration in vitro

J Neurosci

Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia

Proc Natl Acad Sci U S A

Platelet-activating factor inhibits ionotropic GABA receptor activity in cultured hippocampal neurons

Neuroreport

Toward convergence in the medication treatment of bipolar disorder and schizophrenia

Harv Rev Psychiatry

From Kraepelin to Kretschmer leavened by Schneiderthe transition from categories of psychosis to dimensions of variation intrinsic to Homo sapiens

Arch Gen Psychiatry

Specificity of cognitive deficits in bipolar disorder versus schizophreniaa systematic review

Psychother Psychosom

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

Proc Natl Acad Sci U S A

Family history RDC

Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression

Mol Psychiatry

Reelin promoter hypermethylation in schizophrenia

Proc Natl Acad Sci U S A

Cellular neuroscience
Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: A preliminary study